Clinical trials: SLE (Systemic Lupus)
Systemic Lupus Erythematosus Arthritis
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE
This is an exploratory evaluation of MRI as a reliable, sensitive, and accurate outcome measure for clinical trials in SLE arthritis.
- Trial name
- MEASURE (NCT03355482)
- Testing
- Methylprednisolone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Oklahoma Medical Research Foundation
Systemic Lupus Erythematosus, Lupus Nephritis (LN)
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis (LN), Sjogren's Syndrome, Inflammatory Myopathy
- Trial name
- NCT07236762
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Systemic Lupus Erythematosus
Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease
It is well known that the deregulation of immune responses plays a major role in many autoimmune diseases, such as Systemic Lupus Erythematosus (SLE).
- Trial name
- SLE (NCT02270710)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Systemic Lupus Erythematosus
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
This is an open-label, one-arm single-center phase Ⅱa study exploring the efficacy and safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) in two subpopulation group of systemic lupus erythematosus…
- Trial name
- NCT04835883
- Testing
- CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Hanyang University Seoul Hospital
Lupus Nephritis
Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis
Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease.
- Trial name
- REBIOLUP (NCT04449991)
- Testing
- Repeat kidney biopsy
- Where
- Sweden
- Volunteers
- 206 people
- Sponsor
- Karolinska Institutet
Systemic Lupus Erythematosus
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity…
- Trial name
- NCT06411249
- Testing
- Belimumab (GSK1550188)
- Where
- 109 sites in United States, Argentina and 9 more
- Volunteers
- 303 people
- Sponsor
- GlaxoSmithKline
Lupus Erythematosus, Systemic
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine…
- Trial name
- SLE-ARTEMIS (NCT06673043)
- Testing
- Anifrolumab
- Where
- 11 sites in Poland
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
SLE
Telemedicine for Follow-up of Systemic Lupus Erythematosus
Background Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs.
- Trial name
- NCT04368299
- Testing
- Telemedicine, Standard care
- Where
- Hong Kong
- Volunteers
- 144 people
- Sponsor
- Chinese University of Hong Kong
Systemic Lupus Erythematosus
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
This prospective randomized control trial is undertaken to evaluate the safety and efficacy of anti-CD20 monoclonal antibody, rituximab, used as 1. monotherapy, 2.
- Trial name
- NCT00556192
- Testing
- rituximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Systemic Lupus Erythematosus
Healthy Lifestyle Intervention in Patients with Systemic Lupus Erythematosus: the Living Well with Lupus Study
This research program aims to investigate the clinical, physiological, metabolic and molecular effects of lifestyle change in patients with systemic lupus erythematosus with high cardiovascular risk.
- Trial name
- NCT04431167
- Testing
- Living well with Lupus
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo
SLE, Lupus Erythematosus, Systemic
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) may involve a variety of organ systems expressed differently from patient to patient, and so can be difficult to characterize clinically.
- Conditions
- SLE, Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus
- Trial name
- VALUE (NCT03142711)
- Testing
- No Medical Intervention
- Where
- 10 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Lupus Research Alliance
SLE; Drug
Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE
The clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus".
- Trial name
- Lupus (NCT04643067)
- Testing
- KPG-818 low dose in phase 1b, KPG-818 mid dose in phase 1b, KPG-818 high dose in phase 1b
- Where
- 18 sites in United States
- Volunteers
- 64 people
- Sponsor
- Kangpu Biopharmaceuticals, Ltd.
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety…
- Trial name
- NCT03312907
- Testing
- Belimumab, Rituximab, Standard therapy (Including Immunosuppressants)
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Exercise and Systemic Lupus Erythematosus
The investigators hypothesize that a three-month aerobic exercise training program will positively affect the lipid profile, insulin sensitivity , cytokine profile, the cardiovascular parameters and muscle strength in SLE…
- Trial name
- NCT01515163
- Testing
- Exercise training
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- University of Sao Paulo
Systemic Lupus Erythematosus
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
- Trial name
- Tulip SC (NCT04877691)
- Testing
- Medi-546
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Systemic Sclerosis, Other Connective Tissue Disease
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis.
- Conditions
- Systemic Sclerosis, Other Connective Tissue Disease, Systemic Lupus Erythematosus, Dermatomyositis
- Trial name
- NETOSE (NCT06462768)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Lupus Erythematosus, Systemic
Physical Activity in Patients With Systemic Lupus Erythematosus
Background. Systemic lupus erythematosus is a chronic autoimmune disease. Among its main clinical manifestations are musculoskeletal symptoms such as myopathies, arthritis, arthralgias or osteonecrosis.
- Trial name
- NCT06919250
- Testing
- Patients with systemic lupus erythematosus
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- University of Oviedo
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus
The CARRA Registry
This CARRA Registry study will create a foundational database for rheumatic diseases of childhood using a novel informatics infrastructure developed as part of the larger clinical project.
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis
- Trial name
- CARRA Registry (NCT01697254)
- Where
- United States
- Volunteers
- 9,587 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus (SLE)
A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in participants with systemic lupus erythematosus
- Trial name
- NCT07538154
- Testing
- SCTC21C
- Volunteers
- 159 people
- Sponsor
- Sinocelltech Ltd.
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
- Trial name
- EMBRACE (NCT01632241)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 96 sites in United States, Brazil and 4 more
- Volunteers
- 503 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company